The unique fatty acids in royal jelly (RJ), 10-hydroxy-2-decenoic acid and 10-hydroxydecanoic acid are expected to be associated with many health benefits, but little is known on the pharmacokinetics and metabolism. The aim of this study is to confirm the metabolism and pharmacokinetics of RJ fatty acids in humans. Twelve volunteers received RJ capsules or enzyme treated RJ (ETRJ) capsules (800 mg). The other group received two doses of ETRJ tablets (800 mg and 1600 mg). Plasma samples were collected up to 12 h after the RJ intake and urine samples were collected within 24 h after ETRJ tablet consumption. The samples were analyzed by LC/MS/MS. A multivariate analysis of the RJ dose plasma samples detected 2-decenedioic acid (2-DA), sebacic acid (SA), and 3-hydroxysebacic acid (3-HSA) with significantly different intensities (P < 0.05) before and after RJ intake. The area under the concentration (AUC) of 2-DA, SA, and 3-HSA was 2500.05 AE 569.58, 322.57 AE 137.36, and 242.98 AE 58.36 ng h mL À1 , respectively. By enzyme treatment, the AUC of 2-DA, SA, and 3-HSA was significantly increased (P < 0.05). The values of AUC and urinary excretion of these metabolites were dose-dependent. The major RJ fatty acids were metabolized to dicarboxylate, absorbed into the circulation and their absorption increased by enzyme treatment. This study provides useful information that will support studies aimed at clarifying the identity of bioactive RJ constituents and their biological effect, and further the development of RJ.
Introduction
Royal jelly (RJ) is a secretion product of the cephalic glands of honey bees (Apis mellifera L.) and is one of the most attractive functional foods. It is the specic food for the queen honey bee throughout her life period and it is involved in the fertility and longevity of the queen.
1
A multitude of pharmacological activities have been reported in experimental animals [2] [3] [4] [5] [6] and in clinical trials, [7] [8] [9] [10] including antitumor, anti-oxidant, 3 anti-inammatory, 4 antibacterial, 5 and anti-aging, 6 improvement of chills, 7 neck muscle strain, 8 tinnitus, 9 female menopausal symptoms, 10 age associated muscle strength decline, 11 and lipoprotein metabolism by lowering serum total cholesterol and leading to low-density lipoprotein levels, as well.
12
The chemical composition of RJ consists of: water (60-70%), proteins (9-18%), sugars (7.5-23%), lipids (3-8%), and other trace compounds. The two major unique fatty acids in RJ are trans-10-hydroxy-2-decenoic acid (10H2DA) and 10-hydroxydecanoic acid (10HDAA) which comprise 60-80% of RJ lipids. 13 Moreover, the characterizations of fatty acids composition in RJ have been determined as a set of C8, C10, and C12 fatty acids.
14 Several pharmacological activities of 10H2DA and 10HDAA have been reported in animal experiments [15] [16] [17] [18] [19] and these fatty acids are expected to play an important role in the pharmacological activities of RJ.
Generally, medium chain fatty acids (MCFAs) containing 8-12 carbons are absorbed more efficiently than long chain fatty acids and transported in the portal blood directly to the liver, unlike long chain fatty acids. Subsequently, MCFAs enter the mitochondria independently of the carnitine transport system and undergo preferential b-oxidation; the resulting glut of acetyl-CoA derives ketone body production, being linked to many health benets. 20 However, there is little known on the pharmacokinetics of the MCFAs from RJ. In addition, the pharmacokinetic inuence of protease treated RJ, which has been reported to reduce the immunoreactivity and allergenicity of RJ, 21 has not been investigated yet. The aim of this study is to conrm the metabolism and pharmacokinetics of RJ fatty acids in humans. The effect of protease treatment of RJ on the fatty acids absorption is also investigated.
Materials and methods

Chemicals and materials
LC/MS grade methanol was obtained from Kanto Chemical Co., Inc. (Tokyo, Japan) and LC/MS grade acetonitrile and HPLC grade acetic acid were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 10H2DA was purchased from Hangzhou Eastbiopharm, Co.,Ltd. (Hangzhou, China), and 10HDAA was purchased from Combi-Blocks, Inc. (San Diego, USA). 2-Decenedioic acid (2-DA) was purchased from Sundia MediTech Co., Ltd. (Shanghai, China); decanedioic acid (sebacic acid, SA) and 8-hydroxyoctanoic acid were purchased from Sigma-Aldrich Co., LLC. (St. Louis, USA); 3-hydroxysebacic acid (3-HSA) was purchased from Santa Cruz Biotechnology (Dallas, USA); 12-hydroxydodecanoic acid was purchased from MP Biomedicals, LLC. (California, USA); traumatic acid was purchased from Cayman Chemical (Ann Arbor, USA). Dodecenedioic acid and trans-2-heptenoic acid were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 3,10-Dihydroxydecanoic acid was isolated from RJ and obtained by HRFABMS and 13 C NMR data. The spectroscopic data were completely identical to those reported by Melliou and a All values are mean AE SDs; Group A, the subjects received RJ and ETRJ capsules; Group B, the subjects received two dose of ETRJ (800 mg and 1600 mg); BMI, body mass index; ETRJ, enzyme treated royal jelly; RJ, royal jelly. Fig. 1 (A) Flow diagram of participants through the study. ETRJ, enzyme treated royal jelly; RJ, royal jelly; W/O, wash out. (B) Schematic representation of the study design. The subjects ingested RJ for at least 12 h after fasting. The blood samples were obtained before and 30 min, 1 h, 2 h, 4 h, 8 h, and 12 h after RJ intake. In group B, the urine samples were collected before RJ intake and between 0-3, 3-6, 6-12, and 12-24 h after RJ intake.
Chunou. 22 The RJ powder was obtained by freeze drying of RJ and the enzyme treated RJ (ETRJ) powder was obtained by degradation of RJ protein using protease and freeze drying. The RJ powder standardized to contain minimum 3.8% 10H2DA, minimum 0.6% 10HDAA and the ETRJ powder standardized to contain minimum 3.5% 10H2DA, minimum 0.6% 10HDAA, respectively. The capsules were prepared by encapsulating RJ or ETRJ powder in hard capsules and ETRJ tablets were sugar coated containing 9.2% diluents. Both capsules and tablets were obtained from Yamada Bee Company, Inc.
Extraction of RJ fatty acids
Each RJ sample (200 mg) used in clinical trials was extracted with 3 mL methanol and centrifuged at 2000 Â g for 10 min at room temperature; the supernatant was collected into a new vial. The same extraction was repeated three times and collected supernatant was diluted with methanol up to a concentration of 10 mg mL
À1
. The extracts were ltered with a 0.2 mm lter (DISMIC 13HP, Advantec, Tokyo, Japan), and 3 mL of the ltrates were injected into LC/MS/MS system.
Study design and sampling
Twelve volunteers (Group A, 6 men and 6 women, aged 26-33 y) with no apparent diseases participated in this study. One week before the study and during the study, the volunteers were directed not to take RJ, supplements or drinks including RJ. Baseline samples were collected aer a 12 h evening fast. The subjects received RJ capsules or ETRJ capsules (800 mg -4 capsules) in 2 experimental periods separated by 6 day wash-out period. Further, the other twelve volunteers (Group B, 6 men and 6 women, aged 26-32 y) received two doses of ETRJ tablets (800 mg -3 tablets and 1600 mg -6 tablets) in 2 experimental periods separated by 6 day wash-out period. Table 1 shows demographics of the subjects in each group. Blood samples were collected before the RJ intake and at 30 min, 1, 2, 4, 8, and 12 h aer the RJ intake (Fig. 1) . The collected blood samples were centrifuged at 2000 Â g for 3 min at room temperature. The urine samples were obtained before RJ consumption and between 0-3, 3-6, 6-12, and 12-24 h aer the ETRJ tablets consumption. The obtained plasma and urine samples were stored at À80 C until LC/MS/MS analysis. This study design was carried out in accordance with the principles outlined in the Declaration of Helsinki and approved by Yamada Bee Co. Ethics Committee (Registered Japan Agency for Medical Research and Development, No. 16000050). All of the subjects gave their written informed consent.
Plasma and urine samples preparation
For LC/MS/MS analysis, 50 mL of plasma were mixed with 500 mL methanol and centrifuged at 10 000 Â g for 5 min at room temperature. The collected supernatant was evaporated with nitrogen gas and dissolved with 150 mL methanol. The samples were ltered with a 0.2 mm lter, and 3 mL of the ltrates were injected into LC/MS/MS system. Two hundreds mL of urine were centrifuged at 10 000 Â g for 5 min at room temperature and the supernatant was diluted with 800 mL methanol. Centrifugation was performed under the same conditions; the supernatants were evaporated with nitrogen gas and dissolved with 200 mL of 50% methanol solution. The samples were ltered and 3 mL were injected into LC/MS/MS system.
LC/MS/MS analysis
LC analysis was performed using an Ultimate3000 system (Thermo Scientic). Separation of metabolites was performed at 40 C using a reversed phase column (Acquity UPLC BEH C18, 2.1 Â 100 mm, 1.7 mm i. arbitrary units, auxillary gas: 10 arbitrary units, sweep gas: 0 arbitrary units, heater temperature: 400 C, capillary temperature: 250 C, S-lens RF level: 50, and collision energy:
15, 30, 45 eV (normalized stepped collision). The instrument was calibrated using Ultramark 1621 (Thermo Fisher Scientic) prior to the beginning of the analysis.
Data processing and analysis
Thermo Scientic Compound Discoverer version 2.1 soware was used for comparative analysis. Results from differential analysis of aligned chromatographic peaks were ltered requiring a minimum 2-fold change in peak area and signicant increase in peak area between RJ capsules pre-dose and aer-dose samples Fig. 2 Plasma concentration-time curve and AUC of 2-decenedioic acid, sebacic acid, and 3-hydroxysebacic acid in human subjects (mean AE SDs; n ¼ 12) within 0-12 h after ingestion of 800 mg of RJ or ETRJ capsules. The AUC 0-12 h was calculated by the trapezoidal rule. *, ** Significantly different between RJ and ETRJ, *: P < 0.05 and **: P < 0.01 (paired t test). . Pharmacokinetic analysis, maximum plasma concentration (C max ) and the time to reach C max (T max ) were taken directly from observed plasma concentration-time proles. The elimination half-life (t 1/2 ) for the RJ fatty acids was calculated as 0.693/K el , where K el is the slope of the linear regression of the plasma concentration. The area under the plasma concentration-time curve (AUC 0-12 h , ng h mL ) was calculated by the trapezoidal rule up to the last measured data point, 12 h. Data on plasma concentration and AUC values of 2-DA, SA, and 3-HSA acid aer ingestion of RJ capsules and ETRJ capsules were subjected to statistical analysis by using analysis of variance and a paired t test with JMP for Windows 5 (SAS Institute Japan, Tokyo, Japan).
Results
Fatty acids content in RJ
As shown in Table 2 , the fatty acids content in RJ capsules, ETRJ capsules, and ETRJ tablets were as follows 
Qualitative analysis of RJ metabolites in plasma
The blood samples were collected up to 12 h from subjects who received 800 mg RJ capsules. The RJ metabolites have been analyzed by LC/MS/MS. A multivariate analysis of the plasma samples did not reveal the two major fatty acids, 10H2DA and 10HDAA, but revealed the detection in positive and/or negative modes of 21 metabolites with signicantly different intensities (P value < 0.05 and 2 hold change) before and aer RJ capsules intake ( Table 3) . Nine of the 21 metabolites have been putatively identied on the basis of their exact mass, which was compared to those registered in online databases. Three of the putatively identied metabolites were indicated by LC retention time and MSMS fragmentation pattern of standards; 2-DA, SA, and 3-hydroxy derivative of SA (m/z: 217.1082 [M À H] À ).
Pharmacokinetics of RJ fatty acid metabolites
The plasma concentration-time proles of identied fatty acid metabolites in plasma aer the intake of RJ and ETRJ capsules are presented in Fig. 2 and Table 4 . The C max value of 2-DA, SA, and 3-HSA was 815.23 AE 311.13 ng mL À1 , 117.14 AE 61.73 ng mL À1 , and 94.13 AE 46.87 ng mL À1 1 h aer ingestion of 800 mg RJ capsules, respectively. The AUC 0-12 h of 2-DA, SA, and 3-HSA was 2500.05 AE 569.58 ng h mL À1 , 322.57 AE 137.36 ng h mL À1 , and 242.98 AE 58.36 ng h mL À1 , respectively. Meanwhile, the plasma concentration of 2-DA at 30 min and 1 h aer ingestion of ETRJ capsules was signicantly higher than aer the RJ capsules intake (paired t test P < 0.05, P < 0.01). The AUC 0-12 h of 2-DA indicated a signicant difference aer the ETRJ capsules intake as compared to RJ capsules (paired t test P < 0.05). The plasma concentration of SA and 3-HSA at 30 min and 1 h aer ingestion of ETRJ capsules was signicantly higher than aer the RJ capsules intake (paired t test P < 0.05, P < 0.01). The AUC values of SA and 3-HSA aer the ETRJ capsules intake were signicantly different compared with those obtained aer the RJ capsules intake (paired t test P < 0.01). Fig. 3 and 4 show the plasma concentration and urinary excretion of RJ fatty acid metabolites aer ingestion of two doses of ETRJ tablets. The C max of 2-DA, SA, and 3-HSA aer ingestion of 1600 mg ETRJ tablets was 2482. the intake of 800 mg and 1600 mg tablets have been analyzed and the excreted amount of these compounds was calculated from the total amount of urine. As a result, the 10H2DA and 10HDAA were not detected in any fraction (<5 ng mL À1 : data not shown), but 2-DA, SA, and 3-HSA were detected in each urine fraction up to 12 h aer ingestion of ETRJ tablets. (Fig. 4) . Fig. 3 Plasma concentration time curve and AUC of 2-decenedioic acid, sebacic acid, and 3-hydroxysebacic acid in human subjects (mean AE SDs; n ¼ 12) within 0-12 h after ingestion of 800 mg or 1600 mg ETRJ tablets. The AUC 0-12 h was calculated by the trapezoidal rule. n.s., not significant (student's t test).
Dose dependency of plasma concentration and urine excretion of RJ fatty acids
T max (h) t 1/2 (h) C max (ng mL À1 ) AUC 0-12 h (ng h mL À1 ) T max (h) t 1/2 (h) C max (ng mL À1 ) AUC 0
Discussion
This study revealed that fatty acids in RJ were metabolized to dicarboxylic acids, absorbed into the circulation and then excreted in the urine. We also demonstrated that fatty acids in ETRJ were absorbed to a greater extent than those of RJ. Metabolome analysis of plasma aer RJ capsules consumption revealed dicarboxylic acids but not hydroxy fatty acids ingested from RJ, such as: 10H2DA, 10HDAA, and 3,10-dihydroxydecanoic acid. This result indicates that the terminal hydroxyl group of each fatty acid should be oxidized by phase I metabolism in the liver and converted into dicarboxylic acids. Generally, fatty acids undergo two types of oxidation. The most common pathway is stepwise catabolism via b-oxidation and formation of acetyl-CoA. The second type of oxidation are uoxidation where the terminal methyl and methylene position of fatty acids is undergoing conversion to carboxyl. In case of lauric acid, a medium chain fatty acid, it was reported that around 20% of laurate is estimated to undergo u-oxidation. 23 In contrast, almost all of the absorbed 10H2DA and 10HDAA could have undergone u-oxidation because there were no signicant increases in plasma concentration values of 10H2DA and 10HDAA before and aer RJ intake, suggesting that RJ fatty acids could be efficiently u-oxidized compared with other MCFAs, maybe because of the terminal hydroxyl groups.
In this study, we also demonstrated that the gastrointestinal absorption of RJ fatty acids increases with protease treatment of RJ. In the previous study, medium and long chain fatty acids are reported to bind to albumin. 24 In the same way RJ fatty acids might bind to RJ proteins, leading to a low concentration of free fatty acids in the gut and a low passive absorption rate.
Quantitative analysis of RJ plasma metabolites using ETRJ tablets revealed that the AUC values of 2-DA, SA, and 3-HSA were dose dependent (Fig. 3) . The total amounts of urinary 2-DA, SA, and 3-HSA over 24 h aer RJ intake were also dose dependent and completely excreted within 12 h (Fig. 4) , showing that these metabolites could be useful biomarkers of RJ absorption. The pharmacokinetic parameters of RJ fatty acid metabolites were compared between men and women, and the C max values of women were 1.2-to 1.5-fold higher than those in men ( Fig. 3 and Table 5 ). However, considering that men had 1.2-fold higher weights (Table 1) , there would be no gender difference in absorption rate. Further study, such as setting the dose per body weight to reduce the individual differences will be needed to conclude the gender difference.
SA is known to have pharmacological activities, estrogenic effect via estrogen receptor b, 25 TRPA1 and TRPV1 activation, 26 increases GLUT-4 expression in L6 myoblast, 27 and anti-inammatory effect by inhibition of inducing TNF-a.
28
The activity of 2-DA has not been reported so far but might be expected to have similar activities like those described above. In addition, because it has been reported that isotope labeled SA administered intravenously to mice was eliminated about 25% as CO 2 in expired air, 29 it is possible that dicarboxylic acids to be further metabolized to other components such as ketone body. Similarly, other metabolites generated from those dicarboxylic acids could be responsible for the mechanisms of RJ pharmacological activities. Although further investigation will be needed to determine which components exert positive pharmacological effects of RJ in clinical trials, RJ fatty acid metabolites may be responsible for the pharmacological functions of RJ. Fig. 4 Total amount of urine excreted 2-decenedioic acid, sebacic acid, and 3-hydroxysebacic acid in human subjects (mean AE SDs; n ¼ 12) 0-24 h after ingestion of 800 mg or 1600 mg ETRJ tablets.
Conclusions
This study has been established that dicarboxylic acids and their hydroxyl derivatives are absorbed into the circulation and then excreted in the urine. We also found that the fatty acids absorption increased by protease treatment of RJ. Thus, the protease treated RJ will be a promising material not only safe but also effective. Our study claries for the rst time the absorption, metabolism, and pharmacokinetics of fatty acids derived from RJ in human. This work provides the potential of RJ for therapeutic application from the aspects of pharmacokinetics and metabolites and supports studies aimed at clarifying the identity of bioactive RJ constituents and their biological effect.
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